期刊文献+

人冻干重组脑利钠肽联合小剂量多巴酚丁胺对顽固性心力衰竭的疗效观察 被引量:5

Observation of the Effect of Lyophilized Recombinant Human Brain Natriuretic Peptide Jointing Low-dose Dobutamine Used to Refractory Heart Failure
下载PDF
导出
摘要 目的对顽固性心力衰竭患者使用人冻干重组脑利钠肽联合小剂量多巴酚丁胺的疗效进行评估。方法选取顽固性心力衰竭患者120例,随机分为A组、B组和C组各40例,常规基础治疗上,A组给予常规剂量多巴酚丁胺,B组给予人冻干重组脑利钠肽,C组给予人冻干重组脑利钠肽联合小剂量多巴酚丁胺。比较三者临床疗效、左房内径、左心室舒张期末径、左心室射血分数、血浆脑利钠肽等指标。结果 C组对顽固性心力衰竭的疗效明显高于A组、B组;与治疗前比较,三组在治疗后72h左室内径减小,左室射血分数提高,血浆BNP水平下降,但以C组效果尤佳。结论人冻干重组脑利钠肽联合小剂量多巴酚丁胺治疗顽固性心力衰竭效果显著,副作用小。 Objective To evaluate the effect of the patients with Refractory heart failure using Lyophilized recombinant human brain natriuretic peptide jointing low-dose Dobutamine. Methods 120 patients with Refractory heart failure were randomly divided into A group(n=40), B group(n=40) and C group(n=40), A group was treated with conventional-dose Dobutamine, B group was treated with Lyophilized recombinant human brain natriuretic peptide. C group was treated with Lyophilized recombinant human brain natriuretic peptide jointing low-dose Dobutamine. Three groups were compared the effect of heart failure treatment, LAD,LVEDD,LVEF and plasma BNP level.Results Compared with A group and B group, C group's treatment of arrhythmia get best results. Compared with before treatment,three group's LAD ,LVEDD and plasma BNP level decreased,E / A improved, the effect of group C is especially obvious. Conclusion It is effective and safe for the patients with Refractory heart failure to use Lyophilized recombinant human brain natriuretic peptide jointing low-dose Dobutamine.
出处 《中国医药指南》 2013年第34期49-50,共2页 Guide of China Medicine
关键词 顽固性心力衰竭 人冻干重组脑利钠肽 多巴酚丁胺 Refractory heart failure Lyophilized recombinant human brain natriuretic peptide Dobutamine
  • 相关文献

参考文献5

二级参考文献10

  • 1Abraham WT,Lowes BD,Ferguson DA,et al.Systemic hemodynamic,neurohormonal,and renal excretory effects of a steady-state infusion of human brain natriuretic peptide in patients with decompensated chronic heart failure.J Card Fail,1998,4:37-44.
  • 2Mills RM,LeJemtel TH,Horton DP,et al.Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure:a randomized,double-blind,placebo-controlled clinical trial.Natrecor Study Group.J Am Coll Cardiol,1999,34:155-162.
  • 3Colucci WS,Elkayam E,Horton DP,et al.Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated heart failure.N Engl J Med,2000,343:246-253.
  • 4Kawakami R,Saito Y,Kishimoto I,et al.Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction.Circulation,2004,110:3306-3312.
  • 5Keating GM,Goa KL.Nesiritide:a review of its use in acute decompensated heart failure.Drugs,2003,63:47-70.
  • 6de Lemos JA,McGuire DK,Drazner MH.B-type natriuretic peptide in cardiovascular disease.Lancet,2003,362:316-322.
  • 7Strain WD.The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.Int J Clin Pract,2004,58:1081-1087.
  • 8de Denus S,Pharand C,Williamson DR.Brain natriuretic peptide in the management of heart failure:the versatile neurohormone.Chest,2004,125:652-668.
  • 9Colucci WS.Nesiritide for the treatment of decompensated heart failure.J Card Fail,2001,7:92-100.
  • 10Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999

共引文献2637

同被引文献37

  • 1Kawakami R, Saito Y, Kishimoto I, et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction[J]. Circulation, 2004, 110(21):3306- 3312.
  • 2Baruch L, Patacsil P, Hameed A, et al. Pharmacodynamic effects of milrinone with and without a bolus loading infu- sion[J]. Am Heart J, 2001, 141 (2):266-273.
  • 3WRITING COMMITTEE MEMBERS, Yancy C W, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure[J]. Circulation, 2013, 128 (16):e240-327.
  • 4刘陶萍,唐逸,唐国传.前列地尔联合多巴酚丁胺治疗顽固性心力衰竭的临床疗效及安全性分析[J].实用心脑肺血管病杂志,2014,15(10):105-106.
  • 5Ning B, Qi X,Li Y,et aLBiventricular pacing cardiac con- tractility modulation improves cardiac contractile function via upregulating SERCA2 and miR-133 in a rabbit model of congestive heart failure[J].Cell Physiol Biochem,2014, 33(5) : 1389-1399.
  • 6Lu R,Muci,3o-Bermejo MJ,Ribeiro LC,et al.Peritoneal dialysis in patients with refractory congestive heart fail- ure : a systematic review[J].Cardiorenal Med, 2015,5 (2) : 145-156.
  • 7Tsuji A,Ogo T,Demachi J,et al.Rescue balloon pulmonary angioplasty in a rapidly deteriorating chronic throm- boembolic pulmonary hypertension patient with liver fail- ure and refractory infection[J].Pulm Circ, 2014,4(1 ) : 142- 147.
  • 8Liu Y, Li H, Xia W, et al.Electrophysiological effect of rotigaptide in rabbits with heart failure[J].Arch Med Sci, 2014, 10(2) : 374-380.
  • 9陈元龙,王建新.小剂量糖皮质激素佐治顽固性心力衰竭的疗效分析[J].实用心脑肺血管病杂志.2013(12)
  • 10李颖庆,柳娜,符晖,文红艳.米力农与洋地黄治疗充血性心力衰竭的疗效比较[J].中国心血管病研究,2008,6(12):891-893. 被引量:21

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部